A new study funded in part by The Happy Lungs Project found that some RET resistance mutations are resistant to both selpercatinib and pralsetinib, while others affect only one of them, suggesting that knowing a patient’s specific resistance mutation could help guide the most effective treatment.
Selpercatinib (Retevmo) and pralsetinib (Gavreto) have transformed treatment for people with RET fusion-positive non-small cell lung cancer (NSCLC). But most patients eventually develop resistance, and effective options after resistance remain limited. One common way resistance happens is through new “secondary” mutations in the RET gene itself that stop the drug from working.
In a new study published in Clinical Cancer Research by Ximeng Liu and colleagues, the team led by Dr. John Heymach of MD Anderson Cancer Center and Dr. Ralf Kittler of UT Southwestern Medical Center, systematically mapped which RET resistance mutations affect which drugs. They found that some mutations cause resistance to both RET inhibitors, while others are “drug-specific,” meaning a patient whose cancer stops responding to one drug might still respond to another. Find the publication here.
Key Takeaways
- Some resistance mutations are drug-specific. V804E/M mutations caused resistance to selpercatinib but not pralsetinib, while L730I/V and a newly discovered mutation, A883V, caused resistance to pralsetinib but not selpercatinib.
- Some mutations are resistant to both drugs. Solvent-front mutations at G810 (G810C/D/S), as well as Y806N and E732K, caused resistance to both selpercatinib and pralsetinib.
- Next-generation RET inhibitors showed promise. In lab models, vepafestinib was active against several mutations that resist both current drugs, including G810X and Y806N.
- A real-world patient example. One patient whose cancer developed G810C/N mutations on selpercatinib went on to respond to pralsetinib for 22 months.
1
About the Study
The team asked a simple but important question:
To answer it, the team combined five approaches:
Using a method called LentiMutate, the researchers made many small random changes to the two most common RET fusions in lung cancer, KIF5B-RET and CCDC6-RET. They then treated these cells with selpercatinib or pralsetinib. Cells that kept growing had found a way around the drug, and genetic sequencing revealed exactly which change was responsible.
The team rebuilt each mutation individually in Ba/F3 cells, a type of lab cell commonly used to test cancer drugs. By measuring how much drug it took to stop each one from growing, they could see which mutations resisted selpercatinib, which resisted pralsetinib, and which resisted both.
Using 3D computer models of the RET protein, the team examined how each drug fits into RET and how the mutations get in the way. This helped explain why a mutation can block one drug while the other still works.
The same mutant cells were treated with two next-generation RET inhibitors still in clinical trials, zeteletinib and vepafestinib, to see whether they could work where the current drugs could not.
The researchers reviewed records from patients with RET fusion-positive NSCLC treated at MD Anderson between July 2018 and December 2025, focusing on those who had genetic testing both before treatment and after their cancer progressed.
2
Study Results
V804EV804M
Mutations that cause resistance to selpercatinib: V804E and V804M (the “gatekeeper” mutations).
L730I/VA883V
Mutations that cause resistance to pralsetinib: L730I/V and A883V. A883V is a newly identified resistance mutation. Rather than blocking the drug directly, it appears to keep RET switched on during pralsetinib treatment.
G810C/D/SY806NE732K
Mutations that cause resistance to both drugs: G810C/D/S (solvent-front mutations), Y806N, and E732K.
The fusion partner may matter. Some mutations caused stronger resistance when paired with the CCDC6-RET fusion than with KIF5B-RET. Computer modeling suggested this may be because the two fusion proteins have different shapes, although this still needs to be confirmed experimentally.
VepafestinibPralsetinib
Next-generation inhibitors: Vepafestinib was effective in lab models against G810X and Y806N mutations, which resist both current drugs, but not against V804E. Pralsetinib was the most active drug against the selpercatinib-resistant V804E/M mutations.
3
Real-World Patient Data
Among 25 patients with RET fusion-positive NSCLC who had genetic testing before and after treatment, G810 solvent-front mutations were the most common resistance mutations, found in five patients who had all received selpercatinib as their first treatment.
One of them, a 42-year-old man with CCDC6-RET fusion-positive lung cancer, had been on selpercatinib for 23 months when his cancer progressed with G810C and G810N mutations.
He then switched to pralsetinib, had a partial response, and stayed on treatment for 22 months.
Three other patients who received platinum-based chemotherapy after progression had a median progression-free survival of 6 months.
4
Study Limitations
Please note that most of these findings come from laboratory studies, and the clinical observations are based on a small number of patients. More studies are needed to confirm these results and understand how they apply to patients.
5
Conclusions
This study shows that different secondary mutations can affect each RET inhibitor differently, and the type of RET fusion may also play a role. The authors conclude that identifying a patient’s specific resistance mutation at progression, for example through a repeat biopsy or liquid biopsy, could help guide more precise treatment choices. Larger studies are needed to confirm these findings in patients, and next-generation RET inhibitors such as vepafestinib and EP0031 are still being evaluated in clinical trials.
View Latest RET Cancer Treatment News
